The success of the MassArray system in clinical diagnostics is indicative of a broader trend for MALDI-TOF systems that have been approved for clinical use in several regions including the United States, Europe, and China. The upside for this system is throughput, with the system able to run more than 6,000 samples in one day.
Agena bioscience stock pro#
Built to test for and identify clinically relevant mutations, the MassArray system has found a host of important applications in the clinical diagnostics setting, including a Dx Lung Panel, a Dx colon panel, and more recently an Emergency Use Authorization (EUA) for the iPLEX Pro SARS-CoV-2 Panel for qualitative detection of the coronavirus that causes COVID-19. With current yearly revenues around $65 million and an additional $3-$5 million in COVID-19 revenues, Agena Bioscience is expected to greatly contribute to Mesa Laboratories’ solutions lineup.Īn important consideration in this deal was the MassArray system, a combination platform of MALDI-TOF mass spectroscopy and multiplex PCR. The acquisition is expected to be completed by the end of the year pending regulatory approval and met conditions of the agreement. According to the press release, Mesa is expected to pay for the acquisition through cash on hand and credit.
Recently, Mesa Laboratories, a biotech company focused on quality control solutions for pharmaceutical, healthcare, and medical devices, announced the acquisition of Agena Bioscience for a cash purchase price of $300 million. Clinical laboratory diagnostics has become an important area of investment and business transactions.
0 kommentar(er)
